Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses

Olle Ringdén; A. John Barrett; Mei Jie Zhang; Fausto R. Loberiza; Brian J. Bolwell; Mitchell S. Cairo; Robert Peter Gale; Gregory A. Hale; Mark R. Litzow; Rodrigo Martino; James A. Russell; Pierre Tiberghien; Alvaro Urbano-Ispizua; Mary M. Horowitz

doi:10.1046/j.1365-2141.2003.04364.x

Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses

Olle Ringdén, A. John Barrett, Mei Jie Zhang, Fausto R. Loberiza, Brian J. Bolwell, Mitchell S. Cairo, Robert Peter Gale, Gregory A. Hale, Mark R. Litzow, Rodrigo Martino, James A. Russell, Pierre Tiberghien, Alvaro Urbano-Ispizua, Mary M. Horowitz

Hematology

Research output: Contribution to journal › Article › peer-review

65 Scopus citations

Abstract

We studied the association between CD34 cell dose and transplant outcomes in 359 bone marrow (BM) and 511 peripheral blood stem cell (PBSC) transplant recipients from human leucocyte antigen (HLA)-identical siblings, reported to the International Bone Marrow Transplant Registry (IBMTR). Transplants for leukaemia were performed between 1995 and 1998. Patients were divided into those receiving below or above the median CD34⁺ dose, for BM (3 × 10⁶/kg) and PBSC (6 × 10⁶/kg) grafts respectively. Cox proportional hazards regression was used to adjust for baseline patient-, disease- and transplant-related characteristics. Analysis of the BM recipients showed that high CD34 cell dose was associated with lower transplant-related mortality [relative risk (RR)= 0.60, P = 0.033] and treatment failure (inverse of leukaemia-free survival, RR = 0.69. P = 0.032). Among PBSC recipients, high CD34 dose was associated with faster recovery of neutrophils to > 0.5 × 10⁹/l (RR = 1.38, P < 0.001) and platelets to > 20 × 10⁹/l (RR = 1.34, P = 0.003), lower risk of relapse (RR = 0.62, P = 0.029) and treatment failure (RR = 0.74, P = 0.03). We conclude that higher CD34 cell doses decrease treatment failure in recipients of HLA-identical sibling BM and PBSC transplants.

Original language	English (US)
Pages (from-to)	874-885
Number of pages	12
Journal	British journal of haematology
Volume	121
Issue number	6
DOIs	https://doi.org/10.1046/j.1365-2141.2003.04364.x
State	Published - Jun 2003

Keywords

Allogeneic
CD34
Graft type
Leukaemia
Transplantation

ASJC Scopus subject areas

Hematology

Access to Document

10.1046/j.1365-2141.2003.04364.x

Cite this

Ringdén, O., John Barrett, A., Zhang, M. J., Loberiza, F. R., Bolwell, B. J., Cairo, M. S., Gale, R. P., Hale, G. A., Litzow, M. R., Martino, R., Russell, J. A., Tiberghien, P., Urbano-Ispizua, A., & Horowitz, M. M. (2003). Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. British journal of haematology, 121(6), 874-885. https://doi.org/10.1046/j.1365-2141.2003.04364.x

Ringdén, O, John Barrett, A, Zhang, MJ, Loberiza, FR, Bolwell, BJ, Cairo, MS, Gale, RP, Hale, GA, Litzow, MR, Martino, R, Russell, JA, Tiberghien, P, Urbano-Ispizua, A & Horowitz, MM 2003, 'Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses', British journal of haematology, vol. 121, no. 6, pp. 874-885. https://doi.org/10.1046/j.1365-2141.2003.04364.x

@article{d1e251021c7d4391bc6435095d98fa28,

title = "Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses",

abstract = "We studied the association between CD34 cell dose and transplant outcomes in 359 bone marrow (BM) and 511 peripheral blood stem cell (PBSC) transplant recipients from human leucocyte antigen (HLA)-identical siblings, reported to the International Bone Marrow Transplant Registry (IBMTR). Transplants for leukaemia were performed between 1995 and 1998. Patients were divided into those receiving below or above the median CD34+ dose, for BM (3 × 106/kg) and PBSC (6 × 106/kg) grafts respectively. Cox proportional hazards regression was used to adjust for baseline patient-, disease- and transplant-related characteristics. Analysis of the BM recipients showed that high CD34 cell dose was associated with lower transplant-related mortality [relative risk (RR)= 0.60, P = 0.033] and treatment failure (inverse of leukaemia-free survival, RR = 0.69. P = 0.032). Among PBSC recipients, high CD34 dose was associated with faster recovery of neutrophils to > 0.5 × 109/l (RR = 1.38, P < 0.001) and platelets to > 20 × 109/l (RR = 1.34, P = 0.003), lower risk of relapse (RR = 0.62, P = 0.029) and treatment failure (RR = 0.74, P = 0.03). We conclude that higher CD34 cell doses decrease treatment failure in recipients of HLA-identical sibling BM and PBSC transplants.",

keywords = "Allogeneic, CD34, Graft type, Leukaemia, Transplantation",

author = "Olle Ringd{\'e}n and {John Barrett}, A. and Zhang, {Mei Jie} and Loberiza, {Fausto R.} and Bolwell, {Brian J.} and Cairo, {Mitchell S.} and Gale, {Robert Peter} and Hale, {Gregory A.} and Litzow, {Mark R.} and Rodrigo Martino and Russell, {James A.} and Pierre Tiberghien and Alvaro Urbano-Ispizua and Horowitz, {Mary M.}",

year = "2003",

month = jun,

doi = "10.1046/j.1365-2141.2003.04364.x",

language = "English (US)",

volume = "121",

pages = "874--885",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses

AU - Ringdén, Olle

AU - John Barrett, A.

AU - Zhang, Mei Jie

AU - Loberiza, Fausto R.

AU - Bolwell, Brian J.

AU - Cairo, Mitchell S.

AU - Gale, Robert Peter

AU - Hale, Gregory A.

AU - Litzow, Mark R.

AU - Martino, Rodrigo

AU - Russell, James A.

AU - Tiberghien, Pierre

AU - Urbano-Ispizua, Alvaro

AU - Horowitz, Mary M.

PY - 2003/6

Y1 - 2003/6

N2 - We studied the association between CD34 cell dose and transplant outcomes in 359 bone marrow (BM) and 511 peripheral blood stem cell (PBSC) transplant recipients from human leucocyte antigen (HLA)-identical siblings, reported to the International Bone Marrow Transplant Registry (IBMTR). Transplants for leukaemia were performed between 1995 and 1998. Patients were divided into those receiving below or above the median CD34+ dose, for BM (3 × 106/kg) and PBSC (6 × 106/kg) grafts respectively. Cox proportional hazards regression was used to adjust for baseline patient-, disease- and transplant-related characteristics. Analysis of the BM recipients showed that high CD34 cell dose was associated with lower transplant-related mortality [relative risk (RR)= 0.60, P = 0.033] and treatment failure (inverse of leukaemia-free survival, RR = 0.69. P = 0.032). Among PBSC recipients, high CD34 dose was associated with faster recovery of neutrophils to > 0.5 × 109/l (RR = 1.38, P < 0.001) and platelets to > 20 × 109/l (RR = 1.34, P = 0.003), lower risk of relapse (RR = 0.62, P = 0.029) and treatment failure (RR = 0.74, P = 0.03). We conclude that higher CD34 cell doses decrease treatment failure in recipients of HLA-identical sibling BM and PBSC transplants.

AB - We studied the association between CD34 cell dose and transplant outcomes in 359 bone marrow (BM) and 511 peripheral blood stem cell (PBSC) transplant recipients from human leucocyte antigen (HLA)-identical siblings, reported to the International Bone Marrow Transplant Registry (IBMTR). Transplants for leukaemia were performed between 1995 and 1998. Patients were divided into those receiving below or above the median CD34+ dose, for BM (3 × 106/kg) and PBSC (6 × 106/kg) grafts respectively. Cox proportional hazards regression was used to adjust for baseline patient-, disease- and transplant-related characteristics. Analysis of the BM recipients showed that high CD34 cell dose was associated with lower transplant-related mortality [relative risk (RR)= 0.60, P = 0.033] and treatment failure (inverse of leukaemia-free survival, RR = 0.69. P = 0.032). Among PBSC recipients, high CD34 dose was associated with faster recovery of neutrophils to > 0.5 × 109/l (RR = 1.38, P < 0.001) and platelets to > 20 × 109/l (RR = 1.34, P = 0.003), lower risk of relapse (RR = 0.62, P = 0.029) and treatment failure (RR = 0.74, P = 0.03). We conclude that higher CD34 cell doses decrease treatment failure in recipients of HLA-identical sibling BM and PBSC transplants.

KW - Allogeneic

KW - CD34

KW - Graft type

KW - Leukaemia

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0037930786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037930786&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2003.04364.x

DO - 10.1046/j.1365-2141.2003.04364.x

M3 - Article

C2 - 12786798

AN - SCOPUS:0037930786

SN - 0007-1048

VL - 121

SP - 874

EP - 885

JO - British journal of haematology

JF - British journal of haematology

IS - 6

ER -

Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this